190 related articles for article (PubMed ID: 31177574)
1. Co-inhibition of BET proteins and PD-L1 as a potential therapy for OSCC through synergistic inhibition of FOXM1 and PD-L1 expressions.
Wang W; Tan J
J Oral Pathol Med; 2019 Oct; 48(9):817-825. PubMed ID: 31177574
[TBL] [Abstract][Full Text] [Related]
2. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
[TBL] [Abstract][Full Text] [Related]
3. Bromodomain-containing protein 4 inhibition improves the efficacy of cisplatin and radiotherapy in oral squamous cell carcinoma by suppressing programmed cell death-ligand 1 expression.
Ren J
Basic Clin Pharmacol Toxicol; 2024 Feb; 134(2):272-283. PubMed ID: 38014458
[TBL] [Abstract][Full Text] [Related]
4. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
[TBL] [Abstract][Full Text] [Related]
5. All-trans retinoic acid induces anti-tumor effects via STAT3 signaling inhibition in oral squamous cell carcinoma and oral dysplasia.
Chen XJ; He MJ; Zhou G
J Oral Pathol Med; 2019 Oct; 48(9):832-839. PubMed ID: 31323146
[TBL] [Abstract][Full Text] [Related]
6. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.
Hogg SJ; Vervoort SJ; Deswal S; Ott CJ; Li J; Cluse LA; Beavis PA; Darcy PK; Martin BP; Spencer A; Traunbauer AK; Sadovnik I; Bauer K; Valent P; Bradner JE; Zuber J; Shortt J; Johnstone RW
Cell Rep; 2017 Feb; 18(9):2162-2174. PubMed ID: 28249162
[TBL] [Abstract][Full Text] [Related]
7. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
8. PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression.
Zhang Z; Sun D; Tang H; Ren J; Yin S; Yang K
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37914384
[TBL] [Abstract][Full Text] [Related]
9. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.
Jiang L; Wu X; Wang P; Wen T; Yu C; Wei L; Chen H
J Cancer Res Clin Oncol; 2015 Jun; 141(6):971-81. PubMed ID: 25391371
[TBL] [Abstract][Full Text] [Related]
10. Candida albicans induces upregulation of programmed death ligand 1 in oral squamous cell carcinoma.
Wang X; Zhao W; Zhang W; Wu S; Yan Z
J Oral Pathol Med; 2022 May; 51(5):444-453. PubMed ID: 35362187
[TBL] [Abstract][Full Text] [Related]
11. Co-inhibition of adenosine 2b receptor and programmed death-ligand 1 promotes the recruitment and cytotoxicity of natural killer cells in oral squamous cell carcinoma.
Wang B; Wang T; Yang C; Nan Z; Ai D; Wang X; Wang H; Qu X; Wei F
PeerJ; 2023; 11():e15922. PubMed ID: 37663280
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
[TBL] [Abstract][Full Text] [Related]
13. JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression.
Liu K; Zhou Z; Gao H; Yang F; Qian Y; Jin H; Guo Y; Liu Y; Li H; Zhang C; Guo J; Wan Y; Chen R
Cell Biol Int; 2019 Jun; 43(6):642-650. PubMed ID: 30958600
[TBL] [Abstract][Full Text] [Related]
14. TLR9 activation induces immunosuppression and tumorigenesis via PARP1/PD-L1 signaling pathway in oral squamous cell carcinoma.
Ma L; Qin N; Wan W; Song S; Hua S; Jiang C; Li N; Huang L; Gao X
Am J Physiol Cell Physiol; 2024 Feb; 326(2):C362-C381. PubMed ID: 38105756
[TBL] [Abstract][Full Text] [Related]
15. JQ1, a small molecule inhibitor of BRD4, suppresses cell growth and invasion in oral squamous cell carcinoma.
Wang L; Wu X; Huang P; Lv Z; Qi Y; Wei X; Yang P; Zhang F
Oncol Rep; 2016 Oct; 36(4):1989-96. PubMed ID: 27573714
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.
Hölscher AS; Schulz WA; Pinkerneil M; Niegisch G; Hoffmann MJ
Clin Epigenetics; 2018; 10():1. PubMed ID: 29312470
[TBL] [Abstract][Full Text] [Related]
17. FOXM1-Mediated Regulation of Reactive Oxygen Species and Radioresistance in Oral Squamous Cell Carcinoma Cells.
Takeshita H; Yoshida R; Inoue J; Ishikawa K; Shinohara K; Hirayama M; Oyama T; Kubo R; Yamana K; Nagao Y; Gohara S; Sakata J; Nakashima H; Matsuoka Y; Nakamoto M; Hirayama M; Kawahara K; Takahashi N; Hirosue A; Kuwahara Y; Fukumoto M; Toya R; Murakami R; Nakayama H
Lab Invest; 2023 May; 103(5):100060. PubMed ID: 36801643
[TBL] [Abstract][Full Text] [Related]
18. PD-1 Carried on Small Extracellular Vesicles Leads to OSCC Metastasis.
Zhang LZ; Yang JG; Xia HF; Huang J; Liu HM; Wu M; Liu B; Wang WM; Chen G
J Dent Res; 2023 Jul; 102(7):795-805. PubMed ID: 37246810
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R
Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760
[TBL] [Abstract][Full Text] [Related]
20. BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.
Zhu H; Bengsch F; Svoronos N; Rutkowski MR; Bitler BG; Allegrezza MJ; Yokoyama Y; Kossenkov AV; Bradner JE; Conejo-Garcia JR; Zhang R
Cell Rep; 2016 Sep; 16(11):2829-2837. PubMed ID: 27626654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]